[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363313-105":59,"doc-detail-363313-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-tpx2-dependent-lineage-plasticity-by-cdk46-inhibition-reverses-therapy-resistance-in-neuroendocrine-bladder-carcinoma","Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma","","Neuroendocrine bladder carcinoma (NEBC) is an aggressive, therapy-resistant cancer with poor prognosis, and lineage plasticity is implicated in urothelial-to-neuroendocrine transdifferentiation. Transcriptomic analysis of multiple single-cell datasets identifies a TPX2high bladder cancer subpopulation with heightened lineage plasticity and adverse clinical outcomes, lacking canonical neuroendocrine markers. TPX2high cells dysregulate cell-cycle progression and reside in an immunosuppressive niche linked to CD8+ T cell exhaustion. CDK4/6 inhibition combined with immune checkpoint blockade shows strong antitumor efficacy in preclinical organoid and xenograft models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-tpx2-dependent-lineage-plasticity-by-cdk46-inhibition-reverses-therapy-resistance-in-neuroendocrine-bladder-carcinoma/363313/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-tpx2-dependent-lineage-plasticity-by-cdk46-inhibition-reverses-therapy-resistance-in-neuroendocrine-bladder-carcinoma/363313.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study identify about TPX2high cells in bladder cancer?","Question",{"text":112,"@type":113},"The study identifies TPX2high cells as a transitional bladder cancer cell subpopulation with increased lineage plasticity. TPX2high cells lack canonical neuroendocrine markers and correlate with adverse clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are TPX2high cells linked to immune evasion?",{"text":117,"@type":113},"TPX2high cells occupy a suppressive niche associated with CD8+ T cell exhaustion. In vitro and in vivo, TPX2 promotes lineage plasticity and induces T cell exhaustion.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategy is tested against TPX2high and NEBC?",{"text":121,"@type":113},"CDK4/6 inhibition combined with immune checkpoint blockade is tested in preclinical patient-derived organoids and patient-derived xenograft models. The combination shows potent antitumor efficacy for TPX2high and NEBC patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363313,1790194556,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nTargeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance inneuroendocrine bladder carcinoma  \nGraphical abstract Authors  \nZehua Chen (陈泽华), Shengmeng Peng  \n(彭圣萌), Shi Fu (付什), ..., Qiang Zhang (张强), Haifeng Wang (王海峰), Xu Chen  \n(陈旭)  \nCorrespondence  \n[zhangq399@mail.sysu.edu.cn](zhangq399@mail.sysu.edu.cn) (Q.Z.),  \n[wanghaifeng@kmmu.edu.cn](wanghaifeng@kmmu.edu.cn) (H.W.),  \n[chenx457@mail.sysu.edu.cn](chenx457@mail.sysu.edu.cn) (X.C.)  \nIn brief  \nChen et al. identify TPX2high cells as a transitional state enabling bladder tumors to adopt neuroendocrine features and evade immunity. The study shows that CDK4/6 inhibition, combined with immune checkpoint blockade, supports a therapeutic strategy for TPX2high and neuroendocrine bladder carcinoma  \n(NEBC) patients.  \nHighlights  \n• We identify a TPX2high transitional tumor cell subpopulation in bladder cancer  \n• TPX2 promotes G1/S transition and establishes an immunosuppressive niche  \n• CDK4/6 inhibitors are promising for TPX2high and NEBC patients  \nChen et al., 2026, Cell Reports Medicine 7, 102712  \nApril 21, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102712](https://doi.org/10.1016/j.xcrm.2026.102712)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nTargeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma  \nZehua Chen (陈泽华),1,2,8 Shengmeng Peng (彭圣萌),1,2,8 Shi Fu (付什),3,8 Shizhi Lin (林释智),1,2,8 Yiwen Su (速懿雯),4 Xinxin He (何欣欣),5 Yangjie Zhang (张炀杰),1,2 Junlin Lu (卢俊霖),1,2 Sen Liu (柳森),1,2 Hengji Zhan (詹恒基),1,2  \nJianmei Zhong (钟建美),1,2 Baolin Ye (叶保麟),1,2 Chengjunyu Zhang (张成俊煜),1,2 Chu Liu (刘楮),1,2 Bolin Pan (潘柏林),1,2 Haonan Dong (董昊楠),3 Hongqiong Li (李红琼),3 Xinni Ye (叶芯妮),3 Jun Wang (王俊),6 Siting Chen (陈思婷),1,2  \nBaoqing He (何宝晴),1,2 Jingdie Wu (吴境蝶),1,2 Hui Li,7 Qiang Zhang (张强),1,2,* Haifeng Wang (王海峰),3,* and Xu Chen (陈旭)1,2,9,*  \n1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, P. R. China  \n2Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510120, P. R. China  \n3Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P. R. China  \n4Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P. R. China  \n5Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, P. R. China  \n6Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P. R. China  \n7Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA  \n8These authors contributed equally  \n9Lead contact  \n*Correspondence: [zhangq399@mail.sysu.edu.cn](zhangq399@mail.sysu.edu.cn) (Q.Z.), [wanghaifeng@kmmu.edu.cn](wanghaifeng@kmmu.edu.cn) (H.W.), [chenx457@mail.sysu.edu.cn](chenx457@mail.sysu.edu.cn) (X.C.) [https://doi.org/10.1016/j.xcrm.2026.102712](https://doi.org/10.1016/j.xcrm.2026.102712)  \nSUMMARY  \nNeuroendocrine bladder carcinoma (NEBC) is an aggressive and therapy-resistant cancer with poor prognosis. Although lineage plasticity drives urothelial-to-neuroendocrine transdifferentiation, intermediate states remain poorly characterized. Through transcriptomic profiling of public datasets, we define a lineage plasticity-associated signature in bladder cancer. We analyze 64,756 in-house and 201,720 public single-cell transcriptomes from NEBC and urothelial carcinoma (UC), identifying TPX2high bladder cancer cell subpopulation with increased lineage plasticity, supported by multi-cohort histological validation. TPX2high cells lack canonical neuroendocrine markers and are associated with adverse clinical outcomes. TPX2h","cbCaimQvlINQHjbM","https://ap.wps.com/l/cbCaimQvlINQHjbM","pdf",16633302,25,"English","# Summary\n# Highlights\n# Introduction\n## Clinical background of NEBC\n## Molecular features and tumor microenvironment\n# Study focus on lineage plasticity","[{\"question\":\"What does the study identify about TPX2high cells in bladder cancer?\",\"answer\":\"The study identifies TPX2high cells as a transitional bladder cancer cell subpopulation with increased lineage plasticity. TPX2high cells lack canonical neuroendocrine markers and correlate with adverse clinical outcomes.\"},{\"question\":\"How are TPX2high cells linked to immune evasion?\",\"answer\":\"TPX2high cells occupy a suppressive niche associated with CD8+ T cell exhaustion. In vitro and in vivo, TPX2 promotes lineage plasticity and induces T cell exhaustion.\"},{\"question\":\"What therapeutic strategy is tested against TPX2high and NEBC?\",\"answer\":\"CDK4/6 inhibition combined with immune checkpoint blockade is tested in preclinical patient-derived organoids and patient-derived xenograft models. The combination shows potent antitumor efficacy for TPX2high and NEBC patients.\"}]","Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma | PDF",1790150762,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b0be13eba1f5e8653521bfd666cdfa0.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6eb263bc72ff3e8b3506d72d7f368aa1.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a096f142325796f9c1fa5d29da14f233.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b14eddd8cffebab1d9771fe43b8d5134.webp",980,1272]